The International Progressive MS Alliance is about to publish a paper that recommends advancing research on a specific biomarker to predict MS progression, and we're getting a pre-publication preview of what that paper is all about.
The 2020 ACTRIMS-ECTRIMS Virtual Conference 3:10
Boosting cellular energy at sites of myelin loss may stop MS progression 4:18
Why NICE failed to approve Mayzent to treat active secondary progressive MS 6:29
Novartis Innovation Prize awarded to AccessNow 9:04
Elevated neurofilament light chain may predict risk of MS progression 10:02
My Interview with Dr. Robert Fox and Caroline Sincock 11:27
Share this episode 42:11
Please Support the National MS Society COVID-19 Response Fund 42:30
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/149
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
RealTalk MS Episode 149
Hosted By: Jon Strum
Guests: Dr. Robert Fox and Caroline Sincock
Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS